Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Financial Strength

6/10

Name	Current	Vs Industry
Cash-To-Debt	0.26
Equity-to-Asset	0.58
Debt-to-Equity	0.41
Debt-to-EBITDA	2.38
Interest Coverage	8.5
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	2.74	Distress Grey Safe
Beneish M-Score	-2.56	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

2/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	-6.8
	3-Year EBITDA Growth Rate	-26.7
	3-Year EPS without NRI Growth Rate	-11.1
	3-Year FCF Growth Rate	-28.1
	3-Year Book Growth Rate	13.3
	Future 3-5Y EPS without NRI Growth Rate	5.92

Momentum Rank

1/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	49.27
	9-Day RSI	35.36
	14-Day RSI	31.78
	6-1 Month Momentum %	-16.58
	12-1 Month Momentum %	-20.59

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.26
	Quick Ratio	0.8
	Cash Ratio	0.31
	Days Inventory	404.72
	Days Sales Outstanding	78.84
	Days Payable	62.49

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	1.7
	Shareholder Yield %	-0.07

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	75.59
	Operating Margin %	23.17
	Net Margin %	16.81
	FCF Margin %	18.41
	ROE %	10.52
	ROA %	5.91
	ROIC %	8.15
	ROC (Joel Greenblatt) %	37.57
	ROCE %	9.3
	Years of Profitability over Past 10-Year	10

GF Value Rank

8/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	14.44
	Forward PE Ratio	9.5
	PE Ratio without NRI	10.44
	Shiller PE Ratio	7.59
	Price-to-Owner-Earnings	22.63
	PS Ratio	2.41
	PB Ratio	1.42
	Price-to-Tangible-Book	347.46
	Price-to-Free-Cash-Flow	13.08
	Price-to-Operating-Cash-Flow	10.85
	EV-to-EBIT	12.88
	EV-to-Forward-EBIT	10.13
	EV-to-EBITDA	9.99
	EV-to-Forward-EBITDA	7.59
	EV-to-Revenue	2.91
	EV-to-Forward-Revenue	2.99
	EV-to-FCF	15.79
	Price-to-Projected-FCF	0.52
	Price-to-Median-PS-Value	0.59
	Price-to-Graham-Number	12.64
	Earnings Yield (Greenblatt) %	7.76
	FCF Yield %	7.59
	Forward Rate of Return (Yacktman) %	-7.53

Financials (Next Earnings Date:2025-02-13 Est.)

Annual Quarterly TTM

BIIB's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

No Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

No Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

No Enough Data

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

No Enough Data

Guru Trades

See Details

Insider Trades

See Details

Gurus Latest Trades with NAS:BIIB

No Available Data

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015

Biogen Inc Executives

Details

GF Value: $222.81

BIIB

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 4 Severe warning signs with BIIB. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil $)	9,607.5
	EPS (TTM) ($)	11.07
	Beta	0.01
	Volatility %	22.36
	14-Day RSI	31.78
	14-Day ATR ($)	4.164755
	20-Day SMA ($)	165.6045
	12-1 Month Momentum %	-20.59
	52-Week Range ($)	153.62 - 268.295
	Shares Outstanding (Mil)	145.72

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	5
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Biogen Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Biogen Inc Stock Events

Financials Calendars

	Event	Date	Price($)
No Event Data

Biogen Inc Frequently Asked Questions

What is Biogen Inc(BIIB)'s stock price today?

The current price of BIIB is $159.83. The 52 week high of BIIB is $268.30 and 52 week low is $153.62.

When is next earnings date of Biogen Inc(BIIB)?

The next earnings date of Biogen Inc(BIIB) is 2025-02-13 Est..

Does Biogen Inc(BIIB) pay dividends? If so, how much?

Biogen Inc(BIIB) does not pay dividend.

Press Release

	Subject	Date
No Press Release

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.